Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.73 |
| ▸ | APLNR | P35414 | 2/20 | 0.67 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | GLP1R | P43220 | 6/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.61 |
| ▸ | GCGR | P47871 | 5/20 | 0.60 |
| ▸ | GIPR | P48546 | 5/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895442 | 1.00 | CALCR (0.73) | CALCRAPLNRCRHR1CRHR2GLP1R | |
| SCHEMBL29407563 | 0.93 | PTH1R (0.69) | PTH1R | |
| SCHEMBL31182467 | 0.93 | CALCR (0.73) | CALCRAPLNRCRHR1CRHR2GLP1R | |
| SCHEMBL31168252 | 0.92 | CALCR (0.73) | CALCRAPLNRCRHR1CRHR2GLP1R | |
| SCHEMBL30658339 | 0.91 | CALCR (0.73) | CALCRAPLNRCRHR1CRHR2GLP1R | |
| SCHEMBL31139067 | 0.91 | CALCR (0.62) | CALCRPTH1R | |
| SCHEMBL30658226 | 0.91 | CALCR (0.77) | CALCRCRHR1CRHR2GLP1RGCGR | |
| SCHEMBL31182500 | 0.91 | CALCR (0.72) | CALCRAPLNRCRHR1CRHR2GLP1R | |
| SCHEMBL6437072 | 0.91 | CALCR (0.63) | CALCRAPLNRPTH1R | |
| SCHEMBL30658311 | 0.91 | CALCR (0.67) | CALCRAPLNRGLP1RPTH1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | IGISU CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| EP-4014987-A2 | CYCLIC PEPTIDE, AND MEDICINE, EXTERNAL PREPARATION AND COSMETIC EACH CONTAINING SAID CYCLIC PEPTIDE | Igisu Co., Ltd. (JP) | 2022-06-22 | — | — | EP | disclosed |
| CN-114350695-A | Production and purification method and application of disulfide bond-containing polypeptide human brain natriuretic peptide hBNP | 华南理工大学 | 2022-04-15 | — | — | CN | disclosed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221495-B2 | Cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide | TSLP, NPR1, VIP | CALCR 144/4885APLNR 26/4885CRHR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.